Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

Zacks Oct 21 09:10 ET

HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations

PR NewswireOct 21 07:00 ET

We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth

Yahoo FinanceOct 19 10:36 ET

Cathie Wood's ARK Investment Bought 34K Shares of Crispr Therapeutics Today

TipRanksOct 18 20:11 ET

Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating

Moomoo NewsOct 18 07:31 ET · Ratings

Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

TipRanksOct 18 07:05 ET · Ratings